康方生物(09926)发布年度业绩，收入同比增长43.9%至30.56亿元

智通财经03-26

智通财经APP讯，康方生物(09926)发布截至2025年12月31日止年度业绩，该集团取得收入人民币30.56亿元(单位下同)，同比增加43.9%;毛利24.04亿元，同比增加31.01%;研发开支15.75亿元，同比增加32.61%;年内亏损11.41亿元，每股亏损1.23元。作为全球领先的双特异性抗体公司，康方生物2025年继续在世界一流的研发方面取得显著投资进展，同时较2024年缩小了...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2622610318?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-26 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622610318","market":"hk","top_or_hot":-1,"title":"康方生物(09926)发布年度业绩，收入同比增长43.9%至30.56亿元","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康方生物(09926)发布截至2025年12月31日止年度业绩，该集团取得收入人民币30.56亿元(单位下同)，同比增加43.9%;毛利24.04亿元，同比增加31.01%;研发开支15.75亿元，同比增加32.61%;年内亏损11.41亿元，每股亏损1.23元。作为全球领先的双特异性抗体公司，康方生物2025年继续在世界一流的研发方面取得显著投资进展，同时较2024年缩小了...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1420006.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物(09926)发布年度业绩，收入同比增长43.9%至30.56亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物(09926)发布年度业绩，收入同比增长43.9%至30.56亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 23:14 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1420006.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康方生物(09926)发布截至2025年12月31日止年度业绩，该集团取得收入人民币30.56亿元(单位下同)，同比增加43.9%;毛利24.04亿元，同比增加31.01%;研发开支15.75亿元，同比增加32.61%;年内亏损11.41亿元，每股亏损1.23元。作为全球领先的双特异性抗体公司，康方生物2025年继续在世界一流的研发方面取得显著投资进展，同时较2024年缩小了...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1420006.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348735423.USD","symbol_name":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1420006.html","article_id":"2622610318","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622610318","pubTimestamp":1774538074,"columns":[{"name":"行业数据","id":30,"label_key":"dataReport"}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康方生物 发布截至2025年12月31日止年度业绩，该集团取得收入人民币30.56亿元，同比增加43.9%;毛利24.04亿元，同比增加31.01%;研发开支15.75亿元，同比增加32.61%;年内亏损11.41亿元，每股亏损1.23元。作为全球领先的双特异性抗体公司，康方生物2025年继续在世界一流的研发方面取得显著投资进展，同时较2024年缩小了Non-IFRS年内EBITDA，从而提升了财务表现。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","09926":"康方生物","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1161":"生物科技","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK1574":"生物医药B类股","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC"},"translate_title":"Kangfang Bio (09926) released its annual results, with revenue increasing by 43.9% year-on-year to 3.056 billion yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1.5},"content_text":"智通财经APP讯，康方生物(09926)发布截至2025年12月31日止年度业绩，该集团取得收入人民币30.56亿元(单位下同)，同比增加43.9%;毛利24.04亿元，同比增加31.01%;研发开支15.75亿元，同比增加32.61%;年内亏损11.41亿元，每股亏损1.23元。作为全球领先的双特异性抗体公司，康方生物2025年继续在世界一流的研发方面取得显著投资进展，同时较2024年缩小了Non-IFRS年内EBITDA，从而提升了财务表现。除了在2025年推进多项III期临床研究外，公司还将多种新型双特异性抗体推进到临床研究阶段，包括ADC、免疫相关疾病和中枢神经系统疾病等新领域。得益于公司的两款全球首创的双特异性抗体卡度尼利单抗和依沃西单抗等两个产品首次纳入国家医保目录(NRDL)，本报告期内，医保适应症为：卡度尼利单抗注射液用于治疗既往接受含铂化疗治疗失败的复发或转移性宫颈癌、依沃西单抗注射液用于治疗EGFR-TKI治疗后进展的EGFR突变的局部晚期或转移性非鳞状NSCLC;公司2025年的收入同比增长43.9%，从2024年的21.24亿元增至2025年的30.56亿元。新产品的商业化上市也开始对收入增长产生贡献。公司2025年的运营效率持续提升。主要运营费用指标，包括销售及市场费用率、研发费用率和管理费用率，相较于2024年均有所下降。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622610318","isCrawlerRequest":true}